Cover Image

A retrospective analysis of factors associated with the length of hospital stay in COVID-19 patients treated with Nirmatrelvir / Ritonavir

Objectives: This study reviewed factors influencing the length of hospital stay in adult inpatients with confirmed Coronavirus disease (COVID-19) who were treated with Nirmatrelvir/Ritonavir.Methods: We did a retrospective analysis of data from a cohort of inpatients with confirmed diagnosis of Omic...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jiantao Zheng (Author), Wencong Hong (Author), Chanjuan Zhou (Author), Donghuang Hong (Author), Hong Yan (Author), Yanghui Shen (Author)
Format:	Book
Published:	Frontiers Media S.A., 2023-06-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Nirmatrelvir/Ritonavir for hemodialysis patients with COVID-19
by: Jiayue Lu, et al.
Published: (2023)

Nirmatrelvir-ritonavir treatment on SARS-CoV-2 viral dynamics in high altitude habitants
by: Aili Lu, et al.
Published: (2023)

Is the Combination Nirmatrelvir Plus Ritonavir Effective for Treating or Preventing COVID-19?
by: article Editorial
Published: (2022)

Inpatient remdesivir versus nirmatrelvir-ritonavir in the progression of COVID-19
by: Dimple Patel, et al.
Published: (2023)

Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
by: Yuan-Pin Hung, et al.
Published: (2022)

Nirmatrelvir/ritonavir for patients with SARS-CoV-2 infection and impaired kidney function during the Omicron surge
by: Jiayi Yan, et al.
Published: (2023)

Molnupiravir and Nirmatrelvir/Ritonavir: The New Available Antiviral Options for COVID-19
by: Samuel Theodorus Sutanto, et al.
Published: (2022)

Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis
by: Phylinda L. S. Chan, et al.
Published: (2023)

Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
by: Ye Qiu, et al.
Published: (2024)

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability
by: Lili Wang, et al.
Published: (2024)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
by: Meng Li, et al.
Published: (2022)

Evaluation of the drug-drug interactions management system for appropriate use of nirmatrelvir/ritonavir: a retrospective observational study
by: Takeshi Tomida, et al.
Published: (2024)

Managing nirmatrelvir/ritonavir during COVID-19: pharmacists' experiences from the Perak state of Malaysia
by: Chee Tao Chang, et al.
Published: (2022)

Comparative analysis of the safety and effectiveness of Nirmatrelvir-Ritonavir and Azvudine in older patients with COVID-19: a retrospective study from a tertiary hospital in China
by: Nan Shang, et al.
Published: (2024)

Head-to-head comparison of azvudine and nirmatrelvir/ritonavir for the hospitalized patients with COVID-19: a real-world retrospective cohort study with propensity score matching
by: An-Hua Wei, et al.
Published: (2023)

Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2
by: Hui Li, et al.
Published: (2023)

Case report: Application of nirmatrelvir/ritonavir to treat COVID-19 in a severe aplastic anemia child after allogeneic hematopoietic stem cell transplantation
by: Jinhua Huang, et al.
Published: (2022)

Modelling the end of a Zero-COVID strategy using nirmatrelvir/ritonavir, vaccination and NPIs in Wallis and FutunaResearch in context
by: Antoine Brault, et al.
Published: (2023)

Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
by: Ioannis Karniadakis, et al.
Published: (2023)

Case report and literature review: management of Paxlovid (nirmatrelvir/ritonavir)-induced acute tacrolimus toxicity in a patient with systemic lupus erythematosus
by: Chenxiao Jiang, et al.
Published: (2024)

Clinical outcomes of nirmatrelvir-ritonavir use in pregnant women during the Omicron wave of the coronavirus disease 2019 pandemic
by: Chih-Wei Lin, et al.
Published: (2023)

Estudio de utilización de nirmatrelvir/ritonavir en tres centros de atención primaria durante 2022
by: José Miguel Sotoca-Momblona, et al.
Published: (2023)

Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series
by: Hanako Naganawa, et al.
Published: (2024)

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient
by: Eun-Jeong Kwon, et al.
Published: (2022)

Pharmacokinetics Profile and Genetics of Double Antiviral Therapy with Remdesivir and Nirmatrelvir/Ritonavir for Prolonged COVID-19 in Patients Treated with Rituximab: A Real-Life Study and Literature Review
by: Ilaria De Benedetto, et al.
Published: (2024)

MODERN DIRECTED ANTIVIRAL COVID-19 THERAPY: RESULTS OF MULTICENTER CLINICAL EFFECTIVENESS AND SAFETY STUDY OF FIXED NIRMATRELVIR+RITONAVIR COMBINATION
by: L. A. Balykova, et al.
Published: (2022)

Economic Evaluation of Nirmatrelvir/Ritonavir Among Adults Against Hospitalization During the Omicron Dominated Period in Malaysia: A Real-World Evidence Perspective
by: Ee Vien Low, et al.
Published: (2024)

The increasing impact of length of stay "outliers" on length of stay at an urban academic hospital
by: Andrew H. Hughes, et al.
Published: (2021)

Case report: Paralytic ileus resulted from nirmatrelvir/ritonavir-tacrolimus drug-drug interaction in a systemic lupus erythematosus patient with COVID-19
by: Wei Zhang, et al.
Published: (2024)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with preventable mortality, hospital admissions and related avoidable healthcare system cost among high-risk patients with mild to moderate COVID-19
by: Abraham Ka-Chung Wai, et al.
Published: (2023)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
by: Luca Cegolon, et al.
Published: (2023)

Case report: Supratherapeutic tacrolimus concentrations with nirmatrelvir/ritonavir in a lung transplant patient: a case report using Rifampin for reversal
by: Yu Xiong, et al.
Published: (2023)

Insights from a community-based survey on factors influencing acceptance and uptake of Paxlovid (nirmatrelvir and ritonavir) as a COVID-19 antiviral medication in Singapore
by: Sheng En Alexius Matthias Soh, et al.
Published: (2024)

Evaluation of the efficacy and safety of nirmatrelvir/ritonavir co-administration inpatients with rheumatic disease infected with SARS-CoV-2: a real-world study
by: Xue Zhong, et al.
Published: (2023)

Benchmarking and reducing length of stay in Dutch hospitals
by: Heijink Richard, et al.
Published: (2008)

Modelling length of hospital stay in motor victims
by: Mercedes Ayuso-Gutiérrez, et al.
Published: (2015)

The Effects of Natural Daylight on Length of Hospital Stay
by: Man Young Park, et al.
Published: (2018)

COVID in women in Brazil: length of stay and outcomes of first hospitalizations
by: Erica de Brito Pitilin, et al.
Published: (2021)

A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis
by: Ayumi Tsuzawa, et al.
Published: (2023)

Delay in reviewing test results prolongs hospital length of stay: a retrospective cohort study
by: Mei-Sing Ong, et al.
Published: (2018)